+ -coupled solute transport is crucial for the uptake of nutrients and metabolic precursors, such as myo-inositol, an important osmolyte and precursor for various cell signaling molecules. We found that various solute transporters and potassium channel subunits formed complexes and reciprocally regulated each other in vitro and in vivo. Global metabolite profiling revealed that mice lacking KCNE2, a K + channel b subunit, showed a reduction in myo-inositol concentration in cerebrospinal fluid (CSF) but not in serum. Increased behavioral responsiveness to stress and seizure susceptibility in Kcne2 −/− mice were alleviated by injections of myo-inositol. Suspecting a defect in myo-inositol transport, we found that KCNE2 and KCNQ1, a voltage-gated potassium channel a subunit, colocalized and coimmunoprecipitated with SMIT1, a Na + -coupled myo-inositol transporter, in the choroid plexus epithelium. Heterologous coexpression demonstrated that myo-inositol transport by SMIT1 was augmented by coexpression of KCNQ1 but was inhibited by coexpression of both KCNQ1 and KCNE2, which form a constitutively active, heteromeric K + channel. SMIT1 and the related transporter SMIT2 were also inhibited by a constitutively active mutant form of KCNQ1. The activities of KCNQ1 and KCNQ1-KCNE2 were augmented by SMIT1 and the glucose transporter SGLT1 but were suppressed by SMIT2. Channel-transporter signaling complexes may be a widespread mechanism to facilitate solute transport and electrochemical crosstalk.
INTRODUCTION
Voltage-gated potassium (Kv) channel pore-forming a subunits form complexes with a range of ancillary (b) subunits, such as the single-transmembrane domain proteins encoded by the KCNE gene family (Fig. 1A) , leading to various channel subunit compositions with diverse functional characteristics (1) . The KCNQ1 K + channel a subunit is widely distributed in both excitable and nonexcitable cells of vertebrates and is unique among the S4 gene superfamily in that it forms either voltage-activated or constitutively active K + -selective channels, depending on its specific KCNE family b subunit partner (2) . KCNQ1 and KCNE gene disruption is linked to multiple pathologies, often with an unclear molecular etiology. A sequence variant in exon 2 of human KCNE2, a gene associated with the cardiac arrhythmia long QT syndrome (LQTS) (3), has been implicated in a human cardiocerebral phenotype comprising both neonatal seizures and LQTS (4) . In addition, duplication of a 200-kb region containing KCNE1 and KCNE2 has been detected in 16 individuals with schizophrenia but not in 7 control subjects (5) . These findings suggested potential cerebral functions for KCNE2 (a protein we originally named MinK-related peptide 1). KCNE2 protein abundance is relatively low in neuronal tissue, but it is high in the fourth and lateral ventricles, in the apical membrane of the choroid plexus epithelium, where we have also detected KCNQ1 (6) . KCNQ1, which is typically found in complexes with either KCNE2 or KCNE3, each of which renders KCNQ1 constitutively active, is important in various nonexcitable polarized epithelial cell types. In several of these epithelial tissues, KCNQ1-containing channels appear to be prerequisite for the function of ion transporters or symporters, although the molecular mechanisms for this necessity are unclear (6) (7) (8) . Here, while investigating the basis for the increase in neural excitability in Kcne2 −/− mice, we discovered an ion channel-transporter signaling complex, the perturbation of which caused the central nervous system (CNS) metabolite imbalance underlying increased excitability.
RESULTS
Kcne2 gene deletion in mice increased pentylenetetrazole-induced seizure susceptibility and mortality (Fig. 1B) . Because intronic variants in human KCNE2 have also been associated with psychiatric disorders (5), we assessed the behavior of Kcne2 −/− mice. Kcne2 deletion reduced the amount of time spent immobile in the tail suspension test by~40% (which measures depression-like behavior and/or stress responsiveness), indicative of (table S1) . Data points are a three-dimensional projection that summarizes the variance of all CSF features (metabolites) from an individual mouse as three principal components, quantified as coordinates on each of three graphical projections. Results show consistent clustering of CSF metabolites for both Kcne2 +/+ and Kcne2 −/− mice. These genotypes were distinguished by principal component 1 (PC1; quantified on the x axis), which accounted for >38% of total between-genotype variance. (E) Loading plot, depicting the relative contribution of individual features (metabolites) to the betweengenotype variance observed for PC1 and PC2, as depicted in (D). The features that are most distant from the origin in PC1 are those that make the greatest contribution to distinguishing CSF in Kcne2 −/− compared to Kcne2 +/+ mice. The single greatest contributor to PC1 variance (loading −0.948) (red arrow) was later identified as the Na + adduct of myo-inositol (RT, retention time). (F) Extracted ion chromatograms (EICs) for myo-inositol in CSF. Relative abundances for the Na + adduct of myo-inositol in CSF samples were calculated on the basis of the area under EIC curves. The concentration of myo-inositol in CSF was significantly lower in Kcne2 −/− compared to Kcne2 +/+ mice (30% decrease); n = 4 to 5 mice per genotype. ***P < S1 , B and C).
KCNE2 abundance in the CNS is highest in the choroid plexus epithelium (6), which is the major site of cerebrospinal fluid (CSF) production and secretion, but Kcne2 deletion does not substantially perturb CSF K + concentration or pH (6) . We therefore adopted an untargeted CSF metabolomics approach to discover potentially pathological CSF milieu disturbances. Unsupervised principal components analysis (PCA) of liquid chromatography-mass spectrometry (LC-MS) findings demonstrated a robust and consistent difference between CSF from Kcne2 −/− mice and CSF from Kcne2 +/+ mice (Fig. 1D) . We identified the features that contributed most significantly to this intergenotype difference in CSF metabolites on the basis of loading plot values for the PCA analysis (Fig. 1E) . The single greatest contributor to the observed PCA difference was tentatively identified as myo-inositol, which was confirmed by an LC retention time and tandem MS (MS/MS) fragmentation pattern indistinguishable from those of a pure myoinositol standard. Extracted ion counts verified that the 30% reduction in the concentration of myo-inositol in Kcne2 −/− CSF was significant (Fig. 1F) .
This finding was notable for two reasons. First, it was specific because myoinositol was the only metabolite in the CSF whose abundance depended on Kcne2. Second, myo-inositol is actively transported into the CSF from the blood primarily through the choroid plexus epithelium to attain a CSF/blood myo-inositol ratio of >5:1 (11) . In accord with perturbation of the concentration of myo-inositol, which is an important osmolyte, Kcne2 deletion altered choroid plexus epithelial cell shape and volume ( fig. S2 ). Strikingly, acute CSF supplementation of myo-inositol dose-dependently reversed behavioral abnormalities and reduced pentylenetetrazole-induced seizure susceptibility in Kcne2 −/− , but not Kcne2 +/+ , mice (Fig. 1 , G to J), suggesting that these defects were linked to the reduction in CSF myo-inositol in Kcne2 −/− mice. The serum concentration of myo-inositol in Kcne2 −/− mice was not significantly different from that of Kcne2 +/+ mice (Fig. 1H ), a finding that was independently confirmed with a different MS system ( Fig. 2A) , suggesting a local perturbation of myo-inositol active transport at the level of the choroid plexus, rather than a systemic defect in myo-inositol homeostasis. Furthermore, Kcne2 deletion did not alter total SMIT1 protein abundance in mouse choroid plexus epithelium or kidney (Fig. 2B) . Despite the controversy surrounding the role of variations in the CSF concentration of myo-inositol in psychiatric disease (11, 12) , our data suggest that the perturbation in CSF myo-inositol content is associated with a pathological CNS excitability in the Kcne2-deficient mouse. Myo-inositol supplementation did not affect Kcne2 +/+ mice, but normalized two phenotypes indicative of "increased excitability" in Kcne2 −/− mice: increased seizure activity and increased mobility in the tail suspension test, which probably reflect an increased responsiveness to stress (10) and, if validated by antidepressants, could potentially be further interpreted as decreased depressionlike behavior (9) . Na + -coupled myo-inositol transporter SMIT1 (which is encoded by SLC5A3) mRNA has been previously detected in the choroid plexus epithelium (13) . We visualized SMIT1 protein in mouse choroid plexus epithelium, using tissue from Slc5a3 −/− mice as a negative control for immunofluorescence detection. SMIT1 protein was detectable in both the apical and basolateral membranes of the choroid plexus epithelium ( Fig. 2C and fig. S3 , A and B). Kcne2 deletion did not alter the membrane abundance of SMIT1. In some sections, SMIT1 apical membrane abundance was less prominent (Fig. 2D) , possibly reflecting regional variability in or dynamic control of SMIT1 localization, or simply variable antigen accessibility. The presence of SMIT1 on both the basolateral and apical membranes of the choroid plexus epithelium suggests that it could play a role both in myo-inositol uptake from the blood and in removing excess myo-inositol from the CSF.
We detected KCNQ1 and KCNE2 only on the apical membrane of the choroid plexus epithelium (Fig. 2 , E and F) as previously described (6) . We also detected choroid plexus epithelial KCNQ1-KCNE2 and Kv1.3-KCNE2 protein complexes (Fig. 2G ), as expected from our prior functional studies (6) . In addition, we found that KCNE2 and KCNQ1 co-assembled SMIT1-KCNQ1 co-assembly was confirmed in heterologous coexpression studies (Fig. 3A) . When coexpressed in Xenopus laevis oocytes, SMIT1 doubled KCNQ1 outward K + current (Fig. 3 , B and C) without affecting voltage dependence of activation ( fig. S4A ). The current doubling was independent of external myo-inositol (Fig. 3D ) or Na + ( fig. S4B ). SMIT1 similarly doubled KCNQ1-KCNE2 channel current density in a myo-inositol-independent manner (Fig. 3, E and F) . In contrast, SMIT1 neither coimmunoprecipitated with KCNQ4 (which is closely related to KCNQ1) (Fig. 3G ) nor altered KCNQ4 current density, which was also unaffected by SMIT2 (Fig. 3H) .
Reciprocally, coexpression of KCNQ1, but not of KCNQ4, doubled steady-state myo-[ [2] [3] H(N)]inositol uptake by SMIT1, although these channels have similar voltage-dependent activation properties (Fig. 4A) . However, KCNQ1-KCNE2 (but not KCNE2 alone) inhibited SMIT1 steady-state myo-[ [2] [3] H(N)]inositol uptake by~70%, an effect that was not overcome by doubling the amount of SMIT1 complementary RNA (cRNA) injected while maintaining KCNQ1-KCNE2 cRNA constant (Fig. 4B) . This was inconsistent with an exclusively electrochemical gradient-based explanation for KCNQ1 effects on SMIT1 given that KCNE2 converts KCNQ1 to a constitutively active K + channel and therefore drives the membrane potential toward the equilibrium potential for K + (E K ). This membrane hyperpolarization (compared to that of cells expressing the homomeric, voltage-dependent KCNQ1 channel) increases the driving force (under physiological conditions) for inward Na + movement such as occurs during electrogenic myo-inositol active transport, and would therefore be predicted to increase, rather than decrease, myo-inositol uptake by SMIT1 (14) . Similarly, coexpression of a form of KCNQ1 harboring a voltage sensor point mutation (R231A) that confers constitutive channel activation (2) also strongly inhibited SMIT1 activity (~80%; Fig. 4A ). When wild-type KCNQ1 was coexpressed, SMIT1 activity was sensitive to KCNQ inhibitor XE991, a sensitivity that was attenuated by the R231A mutation (Fig. 4C) . SMIT1 myo-[ [2] [3] H(N)]inositol uptake was still Na + -dependent when KCNQ1 was coexpressed (Fig. 4D) .
In contrast to SMIT1, SMIT2 decreased KCNQ1 current by 60% at +60 mV (without affecting KCNQ4; Fig. 3H ). Like SMIT1, the structurally related Na + -dependent glucose transporter SGLT1 augmented KCNQ1 current (by 40%); in contrast, the structurally related Na + -dependent monocarboxylate transporter (SMCT) did not alter KCNQ1 current density (Fig. 5, A and B) . Similar to SMIT1, the effects of SMIT2 and SGLT1 on KCNQ1 did not involve altered voltage dependence and did not require external myo-inositol or Na + ( fig. S4 , A and C to F). SMIT2 also inhibited KCNQ1-KCNE2 current (bỹ 50% at +60 mV; fig. S5, A and B) . The effects of the transporters on channel activity were consistent over multiple oocyte batches (Fig. 5C ).
Macroscopic (whole-oocyte) SMIT2 myo-[ 2-3 H(N)]inositol uptake was suppressed by the R231A-KCNQ1 mutant but not by wild-type KCNQ1 (whether KCNE2 was coexpressed or not) (Fig.  5D ). Wild-type KCNQ1 (whether KCNE2 was coexpressed or not) rendered SMIT2 susceptible to inhibition by the KCNQ1-specific blocker (−)-[3R,4S]-chromanol 293B (Fig. 5E ) without altering sensitivity to phlorizin addition or Na + removal (fig. S5, C and D).
DISCUSSION
Our findings demonstrate the existence of co-regulatory ion channeltransporter signaling complexes in biological systems. Although it is possible that these complexes form to provide proximity such that K + efflux through the channel maintains a local electrical gradient facilitating electrogenic Na + influx, the observed sensitivity of transporter activity to KCNQ1 voltage sensor and/or pore status, with functional effects counter to predicted driving force effects, suggests intimate functional and physical coupling.
Myo-inositol, an osmolyte involved in cell volume regulation, is also a precursor for cell signaling substrates including phosphatidylinositol and phosphatidylinositol phosphate lipids such as phosphatidylinositol 4,5-bisphosphate (PIP 2 ) (15). Because KCNQ1 is both PIP 2 -and cell volumesensitive (16, 17) , direct KCNQ1-SMIT1/2 interaction provides multiple potential feedback mechanisms to control cellular signaling and homeostasis. Notably, Kcne2 deletion suppresses hyperpolarization-activated, cyclic nucleotide-gated (HCN) channel function (I h ) in mouse thalamocortical circuits, increasing intrinsic excitability-enhanced burst firing in response to 4-aminopyridine, despite the relative paucity of neuronal KCNE2 expression (18) . Given that HCN activity is augmented by PIP 2 in vivo and in vitro (19) , it is tempting to speculate that the increased seizure susceptibility of Kcne2 −/− mice arises from altered PIP 2 homeostasis because of a perturbation in myo-inositol transport. However, it may not be as simple as this. Prenatal myo-inositol treatment through maternal drinking water rescues Slc5a3 −/− mice from congenital central apnea, without restoring fetal brain myo-inositol concentrations. Furthermore, there does not appear to be a phosphatidylinositol deficiency in Slc5a3 −/− mice, and the mechanisms underlying both pathology and therapy in Slc5a3 −/− mice are still not well understood (20) . Mechanisms underlying the blood/CSF myo-inositol gradient and its disruption by Kcne2 deletion also remain incompletely resolved. However, on the basis of our data, we suggest that choroid plexus myo-inositol uptake from the blood through basolateral SMIT1 is unaffected, whereas removal of KCNE2 from apical SMIT1-KCNQ1-KCNE2 complexes increases myo-inositol reuptake from the CSF into the choroid plexus epithelium (consistent with data in Fig. 4B ), reducing CSF myo-inositol content. The role of KCNQ1-KCNE2 in CSF myo-inositol homeostasis may affect multiple CNS disorders in which CSF myo-inositol homeostasis has been implicated (21-23), including the cognitive deficits associated with Down syndrome (24) , which is of particular interest because KCNE2 is located on human chromosome 21. KCNQ1-KCNE2 is also required in vivo for normal activity of the sodium iodide symporter and the gastric H + -and K + -dependent adenosine triphosphatase (ATPase) (7, 8, 25) . Furthermore, KCNQ1 gene variants are linked to diabetes (26, 27) , yet the underlying mechanisms have been elusive. It remains to be determined if any of these processes necessitate KCNQ1-transporter complexes, whether KCNQ1 interacts with transporters in excitable cells such as cardiac myocytes, and the extent to which other ion channels and transporters participate in co-regulatory complexes.
MATERIALS AND METHODS

Animal use
We generated and genotyped the Kcne2 −/− mouse line as previously described (24) and housed and used 4-month-old mice according to the U.S. National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals. Animal procedures were approved by the Animal Care and Use Committee at Weill Medical College of Cornell University. The Slc5a3 −/− mouse line was generated as previously described (20, 28) . Animal procedures were approved by the Institutional Animal Care and Use Committee at Boston Children's Hospital. All mice used in this study were generated from heterozygous crosses.
Data presentation and statistics
Continuous data are expressed as means ± SEM of n independent measurements. Dichotomous data are presented as percentages. Statistical comparisons were generally by one-or two-tailed, unpaired Student's t test or one-way analysis of variance (ANOVA) followed by Bonferroni's post hoc test, with one exception: seizure incidence percentages were compared by two-sided z-statistic test for proportions. In all cases, statistical significance was assumed with P < 0.05.
Seizure susceptibility measured by pentylenetetrazole test
Seizure susceptibility measurements were performed as previously described (29) . Briefly, pentylenetetrazole (Sigma-Aldrich) was dissolved in phosphate-buffered saline (PBS) and injected intraperitoneally to a concentration of 40 to 80 mg/kg of body weight. Seizure events were observed over a period of 20 min. Mice were scored by an investigator blinded to genotype, for the sequence of four seizure behaviors produced: myoclonic jerks, clonic convulsions, tonic phase, and death. Timing of the seizures and their duration after pentylenetetrazole injection were recorded. Myoclonus was defined as a single movement of the mouse that involved a downward motion of the head, combined with a single jerk of the body, and a brief upward extension of the tail. Clonus was usually the second seizure behavior to occur chronologically after pentylenetetrazole injection and was defined as rapidly repetitive, often violent jerks of the mouse that involved the entire body, typically ending with the mouse falling to one side. The tonic stage of the seizure, when reached, was defined as a slow hindlimb extension. Tonic stage was in some cases followed by death. Where appropriate, intraperitoneal injection of myo-inositol in vehicle (saline), or of vehicle alone, was performed by a nonscorer 30 min before intraperitoneal injection of pentylenetetrazole.
Behavioral tests
The tail suspension test was performed according to a standard procedure (9) , with the scorers blinded to genotype and content of injections. Where 
CSF metabolomics/MS
CSF was isolated from the cisterna magna of 3-to 6-month-old Kcne2 +/+ and Kcne2 −/− mice using a modification of a previously described technique (31) . Briefly, mice were initially anesthetized with 1% isoflurane in 100% oxygen in a Plexiglas chamber and then placed in a small animal stereotaxic apparatus (model 900, David Kopf Instruments) fitted with a mouse anesthesia mask (David Kopf Instruments) with ear bars to minimize movement of the head. With the head locked in place, the body of the mouse was allowed to drop, allowing access to the neck region. The neck was shaved, an incision was made with a sterile scalpel (no. 10 blade), and the muscles of the neck were separated by blunt dissection to reveal the cisterna magna. Glass borosilicate capillary tubes (B100-78-10, Sutter Instrument), pulled on a vertical micropipette puller (PP-830, Narishige) to generate a tapered tip with an inner diameter of roughly 0.6 mm, were then used to penetrate the cisterna magna, and CSF was drawn into the capillary tubes. A 1-ml syringe with polyethylene tubing attached to the end (to allow tight connection with the capillary tube) was then used to remove the CSF from the capillary tube. CSF samples were then placed on dry ice and transferred to −80°C until analysis. Mice were then sacrificed by CO 2 asphyxiation. For MS data acquisition, CSF samples were extracted 1:20 in 70% acetonitrile containing 0.2% acetic acid, vortexed, and centrifuged at 15,000 rpm for 10 min to remove cell debris. Supernatants were transferred to 250-µl conical polypropylene vials, capped, and loaded into an LC autosampler for analysis. Samples (2 µl) were analyzed with an LC-MS system and platform for untargeted metabolite profiling. A 1200 Series LC system (Agilent Technologies) with a 2.1 × 150-mm Cogent Diamond Hydride column (3.5-µm particle size, MicroSolv Technology Corp.) was used for chromatographic separation. MS analysis on post-column flow used the Agilent Series 6230 Accurate Mass time-of-flight (TOF) mass spectrometer, equipped with dual spray electrospray ionization source, operating in positive ion mode.
LC parameters for aqueous normal-phase separation were as follows: injection volume, 2 µl; column temperature, 25°C; mobile phase flow rate, 0.4 ml/min. The mobile phase consisted of 0.2% acetic acid in doubledistilled water (solvent A) and 0.2% acetic acid in acetonitrile (solvent B) with gradient steps as follows: 0 to 2 min, 85% B; 2 to 3 min, to 80% B; 3 to 5 min, 80% B; 5 to 6 min, to 75% B; 6 to 7 min, 75% B, 7 to 8 min, to 70% B; 8 to 9 min, 70% B; 9 to 10 min, to 50% B; 10 to 11 min, 50% B, 11.0 to 11.1 min, 20% B; 11.1 to 14 min, 20% B; 14 to 14.1 min, 5% B; 14.1 to 24 min, 5% B; 24 to 24.1 min, 85% B; and 24 to 34 min, 85% B. A separate isocratic pump delivered reference mass solution [ion mass/charge ratio (m/z) 121.0509 and 922.0093] for continuous mass calibration during sample analysis. Spectra were acquired in 2 GHz (extended dynamic range) mode with 1.71 spectra/s sampled over an m/z range of 50 to 1000 daltons. The TOF capillary voltage was set at 4000 V, and the fragmenter at 175 V; the nebulizer pressure was 35 psi, and 250°C nitrogen drying gas was delivered at a flow rate of 12 liters/min.
MS data analysis
Raw data files were processed using Agilent MassHunter Qualitative Analysis Software (B346). Molecular feature extraction generates information in features (compounds) that are stored in files for downstream comparative data analysis by Mass Profiler Professional Software (Agilent). The analytical approach uses an algorithm for data alignment across multiple groups and treats all imported files as a single data set. After feature alignment and quality control, the unsupervised pattern recognition algorithm PCA was chosen to examine data sets for similarly changing features, expected and unexpected clusters, and the presence of outlying samples. Compounds determined to be differentially expressed on the basis of statistical criteria and PCA results were assigned tentative formulae by using a molecular formula generator (MFG) algorithm in Mass Profiler Professional or MassHunter Qualitative Analysis. The MFG algorithm assigned molecular formula on the basis of an optimized goodness of fit, considering accurate measurements of mass defect, natural isotopic abundance rations, and spacing between isotope peaks. A putative compound ID was tentatively assigned according to the MFG score and confirmed by comparison with retention times and MS/MS fragmentation of pure chemical standards.
Confirmatory quantification of myo-inositol in serum
Myo-inositol was purchased from Sigma-Aldrich. LC-MS-grade acetonitrile, methanol, and sonic dismembrator model 100 were purchased from Fisher Scientific. The internal standard, [ 2 H 6 ]-myo-inositol (MID6), was purchased from Cambridge Isotope Laboratories Inc.
Mouse serum was obtained by cardiac puncture in anesthetized mice for the collection of whole blood. The serum was deproteinized by addition of 4 volumes of 20 µM MID6 prepared in acetonitrile/water (80:20, v/v) to 1 volume of serum samples. The samples were vortexed thoroughly and centrifuged at 14,000 rpm for 15 min. The supernatant was removed and diluted 10-fold with MQ water. Samples were vortexed and centrifuged again before LC-MS/MS analysis. All serum samples were prepared in duplicates.
For calibration standards, stock solutions of myo-inositol were prepared in MQ water at a final concentration of 10 mM. The calibration standard concentrations were 500, 125, 31.25, 7.81, and 1.95 µM of myo-inositol, also prepared in MQ water. Twenty microliters of each standard was mixed with 80 µl of 20 µM MID6 and 900 µl of MQ water.
A Shimadzu Prominence high-performance liquid chromatography (HPLC) system was used to separate samples and standards with a SUPELCOGEL Pb column (300 × 7.8 mm, 5 µm; Supelco). The injection volume was 20 ml, and the column temperature was set at 85°C. The HPLC protocol consisted of an isocratic gradient of 100% MQ water over a 45-min period. The flow rate was 0.5 ml/min and was diverted to waste from 0 to 16 min and from 28 to 45 min. The HPLC was coupled to a triple quadrupole tandem mass spectrometer equipped with an electrospray ionization source (AB Sciex QTRAP5500). It was operated in negative mode with the following settings: curtain gas 50, ion spray voltage −4500 V, dissolvation temperature 550°C, gas1 40, gas2 40, and declustering potential and collision energy −60, −23 for inositol transition 179.0/87.0 and −55, −15 for MID6 transition 185.1/167.0, respectively. LC-MS/MS peak areas were integrated using Analyst 4.0 software. Further data analysis was performed on Excel (Microsoft).
Electron microscopy
For electron microscopy, choroid plexus tissue from the fourth ventricle of Kcne2 +/+ and Kcne2 −/− mice (two per gender per genotype) was washed, fixed, stained, dehydrated, and then infiltrated and embedded in Spurr's resin. Sections were cut, contrasted with lead citrate, and viewed on a JSM 100 CX-II electron microscope (JEOL USA Inc.) operated at 80 kV. Images were recorded on Kodak 4489 Electron Image film and then digitized on an Epson Expression 1600 Pro scanner at 900 dpi.
Immunofluorescence detection
Tissue samples from Kcne2
+/+ and Kcne2 −/− mice were fixed in 4% paraformaldehyde solution (Electron Microscopy Sciences), followed by incubation in 30% sucrose overnight at 4°C. Embedding was performed in an optimal cutting temperature compound (Tissue-Tek), and embedded samples were stored at −80°C. Frozen samples were cut into 10-mm-thick sections (Cryomicrotome CM 1850, Leica Microsystems). Immunofluorescence detection of Kcnq1, Smit1, and Nkcc1 was performed by either of two methods. First, with a Discovery XT processor (Ventana Medical Systems), goat polyclonal anti-KCNQ1 (pan-species) primary antibody (Santa Cruz Biotechnology, #SC-10646) was used at 1 mg/ml, mouse monoclonal anti-NKCC1 (Santa Cruz Biotechnology) at 1:500 dilution, and rabbit polyclonal anti-SMIT1 (Santa Cruz Biotechnology) at 1:500 dilution. Preceding the primary antibody incubation, tissue sections were blocked for 30 min in 10% normal goat, rabbit or mouse serum, 2% bovine serum albumin in PBS, followed by an 8-min avidin/biotin block. The primary antibody incubation (3 hours) was followed by incubation with biotinylated antibodies against rabbit, mouse, or goat immunoglobulin G (IgG) as appropriate (ANC kit from Vector Labs). The secondary detection was performed with Streptavidin-HRP D (Ventana Medical Systems), followed by incubation with tyramide-Alexa Fluor secondary antibodies (Invitrogen). Alternatively, for images in Fig. 2, C and D, and fig. S3 , immunofluorescence detection was performed manually, with the experimenter blinded to the mouse genotype, after fixing/permeabilizing sections in ice-cold acetone for 10 min. Biotinylation was not used for this approach; other experimental details were similar. Immunostained slides were viewed with an Olympus BX51 microscope, and pictures were acquired using cellSens software (Olympus).
X. laevis oocyte preparation
cRNA transcripts encoding human KCNE2, KCNQ1, R231A-KCNQ1 (2), KCNQ4, SMIT1, SMIT2, SGLT1, and SMCT were produced from linearized complementary DNA (cDNA) templates with the T3 or T7 mMessage mMachine kit (Ambion). SMIT1 cDNA was purchased from Origene; SMIT2 and SGLT1 clones were a gift from M. J. Coady and J.-Y. Lapointe (GÉPROM, Université de Montréal); SMCT cDNA was a gift from N. Carrasco (Yale University). Channel subunit and transporter cRNA was quantified by spectrophotometry, and size integrity was verified by gel electrophoresis. Defolliculated stage Vand VI X. laevis oocytes (Ecocyte Bioscience) were injected with one or more of the cRNAs above (KCNQ1, 10 ng; KCNE2, 4 ng per oocyte; transporters, 5 to 25 ng per oocyte as described in the text). Oocytes were incubated at 16°C in ND96 solution containing penicillin and streptomycin with daily washing, for 4 to 5 days before functional or biochemical assays.
Two-electrode voltage clamp and myo-[ 2-3 H(N)]inositol flux assays
Two-electrode voltage clamp (TEVC) recordings were performed at room temperature using an OC-725C amplifier (Warner Instruments) and pClamp8 software (Molecular Devices), 4 to 5 days after cRNA injection. Oocytes were bathed in a small-volume oocyte bath (Warner) and viewed with a dissection microscope. The bath solution contained 96 mM NaCl, 4 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 10 mM Hepes (pH 7.6) (4K + /96Na + solution) with or without Na + replacement by NMDG and/or addition of phlorizin (500 µM) and/or myo-inositol (1 mM); bath chemicals were from Sigma-Aldrich unless otherwise indicated. TEVC pipettes were of 8-megohm resistance when filled with 3 M KCl. Currents were recorded with a voltage protocol consisting of 3-s pulses between −120 and 60 mV at 20-mV intervals, each followed by a 1-s tail pulse to −30 mV, from a holding potential of −80 mV.
TEVC data analysis was performed with pClamp8, Excel (Microsoft), and Origin 6.1 (OriginLab Corp.). Values are presented as means ± SEM. Normalized tail current was plotted versus prepulse voltage and fitted with a single Boltzmann function according to the following formula:
where g is the normalized tail conductance, A 1 is the initial value at −∞, A 2 is the final value at +∞, V 1/2 is the half-maximal voltage of activation, and V s is the slope factor. KCNQ1 current activation curves were fitted with a standard (zero-shift) double exponential function with a Chebyshev fourpoint smoothing filter.
Radiolabeled myo-inositol uptake assays using myo-[ [2] [3] H(N)]inositol (American Radiolabeled Chemicals Inc.) were performed 5 days after oocyte cRNA injection. For each condition/expression group, 6 to 12 oocytes were placed in a round-bottomed, 10-ml culture tube, washed, and resuspended in ND96 or NMDG-substituted ND96 (200 µl per tube) containing myo-[ 2-3 H(N)]inositol (3 µCi/ml) with or without phlorizin (Sigma) (500 µM), XE991 (Sigma) (10 µM), or C293B (Tocris) (20 mM). After 30 min at room temperature, oocytes were washed two to three times in 3 ml of ND96 or NMDG-substituted ND96 containing 1 mM cold myo-inositol (Sigma), followed by one to two washes in 3 ml of ND96. Oocytes were next individually placed in wells of a 96-well plate and lysed in 100 µl of 2% SDS in ND96; each lysed oocyte was then transferred to a scintillation vial (1 oocyte per vial) containing Ready Protein Plus scintillation fluid (Beckmann Coulter) (6 ml). Vials were capped, shaken vigorously, then allowed to sit at room temperature for at least 30 min before scintillation counting in a Beckmann Coulter 6500. Each experiment was performed on several batches of oocytes from different deliveries as described in the figure legends; results presented are either raw data from a single representative batch or, in some cases, pooled data from two or more batches normalized to the mean value of uptake of the intra-batch control group (either transporter alone or in the absence of inhibitor).
Protein biochemistry
For choroid plexus epithelial studies, adult Kcne2 +/+ and Kcne2 −/− mice were sacrificed by CO 2 asphyxiation, and the choroid plexus was removed from the fourth ventricle of the brain. Tissue samples were then snap-frozen in liquid N 2 for use in Western blot analysis. Whole choroid plexus cell lysates were isolated (32), resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred onto polyvinylidene difluoride (PVDF) membranes for Western blot analysis using standard techniques and equipment (Bio-Rad). Kidney tissue was similarly harvested and analyzed. PVDF membranes were incubated for 3 hours at room temperature in 5% milk with primary antibodies, diluted as follows: rabbit polyclonal anti-KCNE2 (in-house), 1:1000; goat polyclonal anti-KCNQ1 (Santa Cruz Biotechnology), 1:1000; GAPDH (Bio-Rad), 1:100. For secondary detection, horseradish peroxidase (HRP)-conjugated species-appropriate IgG antibodies (1:10,000; Bio-Rad) were used. Signals were detected with ECL-Plus chemiluminescence (Amersham Bioscience) and analyzed with a Gbox system using Gbox software (Syngene).
For X. laevis oocyte biochemistry, membrane fractions were prepared from oocytes injected with the appropriate cRNAs (see next section) as follows: 5 to 10 oocytes per group were homogenized in 1 ml of lysis buffer containing: 0.3 M sucrose, 10 mM sodium phosphate, and 1 mM EDTA supplemented with protease inhibitor cocktail (Sigma). The homogenate was subjected to a low-spin centrifugation (4000 rpm, 15 min, 4°C) to remove yolk protein and cell debris. Membrane fractions were then pelleted at 40,000g for 10 min for coimmunoprecipitation and/or Western blot analysis. Protein concentrations were determined using the bicinchoninic acid (BCA) method (Pierce). For Western blots, up to 5 µg of total protein was mixed with sample buffer and applied on 4 to 12% bis-tris SDS-PAGE gels (Invitrogen). After electrophoresis, proteins were transferred onto nitrocellulose membranes (VWR). The membranes were incubated with goat anti-KCNQ1 polyclonal IgG (1:500, Santa Cruz Biotechnology), rabbit anti-SMIT1 (1:500, Santa Cruz Biotechnology), rabbit anti-SMIT2 (1:1000, MBL International), or rabbit anti-KCNQ4 (1:500, Santa Cruz Biotechnology). HRP-conjugated goat anti-rabbit or rabbit anti-goat IgG secondary antibody (Bio-Rad) was used for visualization with chemiluminescence ECL (Millipore). Signals were analyzed with a Gbox system using Gbox software (Syngene).
For coimmunoprecipitations, whole choroid plexus epithelial cell lysates or X. laevis oocyte crude membrane fractions were incubated with goat anti-KCNQ1 polyclonal IgG (1:500, Santa Cruz Biotechnology), mouse monoclonal anti-Kv1.3 (1:500, NeuroMabs), mouse monoclonal anti-NKCC1 (1:500, Santa Cruz Biotechnology), rabbit anti-SMIT1 (1:500, Santa Cruz Biotechnology), or rabbit anti-KCNQ4 (1:500, Santa Cruz Biotechnology) for 4 to 12 hours before precipitation with protein A/G agarose beads (Pierce). The reactions were washed three to four times, and samples were eluted before immunoblotting as described above.
For CHO cell biochemistry, CHO cells were transfected with cDNAs for KCNQ1 and/or SMIT1-DDK-MyC (Origene). Two days after transfection, cells were lysed in buffer containing 150 mM NaCl, 1% IGEPAL, 50 mM tris (pH 8.0), and 0.1% SDS. Lysates were centrifuged at 3000g for 15 min at 4°C, and the pellets were discarded. Lysates were normalized by total protein content (BCA Protein Assay kit, Pierce), mixed with NuPAGE LDS sample buffer (Life Technologies) supplemented with 5% b-mercaptoethanol, vortexed, heated at 37°C for 10 min, then briefly centrifuged at 1000g for 3 min at room temperature. Lysate samples were then separated using a Nu-PAGE 4 to 12% bis-tris gel with NuPAGE Antioxidant (Life Technologies) in Mops running buffer. After electrophoresis, proteins were transferred onto either PVDF or nitrocellulose membranes in the following buffer: 0.037% lithium dodecyl sulfate (LDS), 20% methanol, 48 mM tris base, 39 mM glycine. The membranes were then blocked in a solution of PBST (PBS + 0.1% Tween 20) + 5% nonfat milk powder and incubated at room temperature for 1 to 2 hours. The membranes were incubated overnight at 4°C in fresh PBST + 5% milk containing mouse monoclonal anti-DDK (1:2000) (Origene) or goat polyclonal KCNQ1 (1:1000) (Santa Cruz Biotechnology). After being washed, the membranes were incubated in PBST + 3% milk solution containing HRP-conjugated secondary antibodies (1:5000, Bio-Rad) for 1 hour at room temperature. After further washing, the membranes were incubated with Luminata Forte Western HRP substrate for 5 min and imaged with a Syngene G Box.
For CHO cell coimmunoprecipitations, 100 µg of total protein from each lysate sample was diluted with lysis buffer to 500 µl of total volume and then precleared with protein A/G PLUS agarose beads (Santa Cruz Biotechnology). After the preclear step, the beads were pelleted by a 5-min spin at 1000g (4°C), and the supernatant was transferred to a new tube. Immunoprecipitation antibodies, goat polyclonal anti-KCNQ1 (Santa Cruz Biotechnology) or mouse monoclonal anti-DDK (Origene), were added to a dilution of 1:100 for overnight incubation at 4°C. The following day, fresh protein A/G PLUS agarose beads were washed in lysis buffer, pelleted, and reconstituted in lysis buffer to a 50% suspension (v/v). Forty microliters of this suspension was added to each of the immunoprecipitation tubes and mixed end-over-end for 4 hours at 4°C. The beads were then pelleted and washed with lysis buffer (3 × 5 min), and then the proteins were eluted into NuPAGE LDS sample buffer for SDS-PAGE and Western blotting as described above.
SUPPLEMENTARY MATERIALS
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